Spero Therapeutics Financial Results
Spero Therapeutics reported third quarter 2026 financial results, ending the period with $107.9 million in cash and cash equivalents. The company is focused on advancing its in-licensed anti-CD40L antibody, SP001, toward a Phase 2 trial in IgG4-related disease expected to initiate in Q2 2027.
“We believe SP001 represents a compelling opportunity to address significant unmet medical needs across multiple immune-mediated diseases. With a strong financial position and the recent additions to our team that strengthen the capabilities needed to support our next stage of development, we believe we are well positioned to execute our clinical development strategy.”
Esther Rajavelu, President and Chief Executive Officer